vimarsana.com

Page 92 - ஒன்றுபட்டது கிஂக்டம் கேரியர் வேலைநிறுத்தம் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DAMEN SHIPREPAIR AMSTERDAM READIES HNLMS EVERTSEN FOR VOYAGE TO JAPAN | Hellenic Shipping News Worldwide

DAMEN SHIPREPAIR AMSTERDAM READIES HNLMS EVERTSEN FOR VOYAGE TO JAPAN After a six-week period of maintenance, Damen Shiprepair Amsterdam has this week handed the HNLMS Evertsen back to the Royal Netherlands Navy. The shipyard worked hard – together with its Dutch suppliers – to prepare the Air Defence and Command frigate for deployment on, among other things, the voyage of nearly 40,000 kilometres that she will soon be making to Japan together with the UK Carrier Strike Group. HNLMS Evertsen is one of the four air defence and command frigates (LCF) of the De Zeven Provinciën class. Under the leadership of Damen Naval in Vlissingen, these advanced LCF frigates were built between 1998 and 2005 by the Dutch maritime industry. At the time, more than 80 percent of the production value was accounted for by Damen’s Dutch maritime suppliers, mostly SMEs, which underlines the self-creative capabilities of this sector.

Royal Netherlands Navy frigate HNLMS Evertsen set for voyage to Japan

15 April 2021 (Last Updated April 15th, 2021 17:51) Damen Shiprepair Amsterdam has delivered the Royal Netherlands Navy’s De Zeven Provinciën-class guided missile frigate HNLMS Evertsen (F805) after completion of maintenance works. Share Article HNLMS Evertsen (F805). Credit: Damen Shipyards Group. Damen Shiprepair Amsterdam has delivered the Royal Netherlands Navy’s De Zeven Provinciën-class guided missile frigate HNLMS Evertsen (F805) after the completion of maintenance works. HNLMS Evertsen (F805) will become part of the UK Carrier Strike Group (CSG) from next month with Japan as its final destination. F805 is the fourth air defence and command frigates (LCF) of the class that was commissioned in June 2005.

Transatlantic Trade US and Europe – April 5, 2021

COVID-19 Updates | EU, UK, US The AstraZeneca COVID-19 vaccine, recently renamed Vaxzevria, made headlines this week in Europe, due to rising concerns over the links with its use and the development of blood clots.  The European Medicines Agency (EMA) again reviewed the data on the reported cases and published another opinion on 7 April 2021, confirming there is a potential link with “very rare cases of unusual blood clots with low blood platelets”.  While the EMA’s safety committee recognized that some of the blood clots cases are linked to the vaccine, it stressed,  “[T]he overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects”.  The EMA confirmed that unusual blood clots should be listed as a very rare side effect, but considering the benefits of the vaccine overall, it remains approved in the EU for people above 18 years old.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.